RxDoctor Payments Data

Jessica Ice, PA

Physician Assistant · Bloomfield, KYNPI 1346261013

Payments from drug & device makers

$469in general payments, 2019–2025

Across 29 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$168
  • AbbVie$89
  • Pfizer$59
  • Sanofi-aventis U.S. LLC$39
  • AstraZeneca$38
  • Dexcom, Inc.$33
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC10$168
AbbVie5$89
Pfizer3$59
Sanofi-aventis U.S. LLC3$39
AstraZeneca3$38
Dexcom, Inc.2$33
Abbott1$18
GSK1$14
Merck1$11

How this compares

$469 in reported general payments places this provider in the 55th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$78,960
Medicare patients
256
Services billed
2,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$81,614
OzempicSemaglutide51$56,275
JanuviaSitagliptin Phosphate34$34,014
JardianceEmpagliflozin22$29,262
EliquisApixaban28$28,688
FarxigaDapagliflozin Propanediol18$22,879
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,244
Tresiba Flextouch U-200Insulin Degludec12$8,401
LinzessLinaclotide16$8,228
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$5,494
NexiumEsomeprazole Magnesium11$5,459
Colestipol Hcl30$2,059
Levothyroxine Sodium294$1,764
Verapamil Er PmVerapamil Hcl12$1,584
Pantoprazole Sodium133$1,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$168$81,61481 claims
MerckJanuvia$11$34,01434 claims
PfizerEliquis, Paxlovid$59$30,11740 claims
AstraZenecaFarxiga, Nexium$38$28,33829 claims
GSKTrelegy Ellipta$14$13,24421 claims
AbbVieLinzess, Synthroid$89$9,39452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Bloomfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →